Healthcare / Pharmaceutical RetailersTokyo
$1805.00
-38.00 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $7.2B · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$67.8B
P/E
9.1x
↓EV/EBITDA
3.8x
↓ROE
9.0%
↑Gross Margin
14.8%
↓Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
—
FCF margin
-3.5%
FCF / Net income
-1.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $263.97B · net income $5.16B · FCF $-9.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $263.97B | $263.97B | $180.05B | $170.04B | $166.20B |
| Net Income | $5.16B | $5.16B | $4.88B | $5.66B | $5.49B |
| EBITDA | $21.42B | $21.42B | $14.21B | $14.56B | $14.52B |
| EPS | 137.97 | 137.97 | 131.11 | 152.96 | — |
| Gross Margin | 14.8% | 14.8% | 12.9% | 13.8% | 13.9% |
| Operating Margin | 5.1% | 5.1% | 4.6% | 5.6% | 5.9% |
| Net Margin | 2.0% | 2.0% | 2.7% | 3.3% | 3.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.72 | 0.72 | 0.60 | 0.47 | 0.53 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.33B | $-9.33B | $11.22B | $7.15B | $8.38B |
| Returns | |||||
| ROE | 9.0% | 9.0% | 9.2% | 11.6% | 12.5% |
| Valuation | |||||
| P/E | 9.15 | 9.15 | 12.95 | 7.56 | — |
| EV/EBITDA | 3.82 | 3.82 | 4.75 | 3.21 | 3.32 |
| P/B | 1.18 | 1.18 | 1.20 | 0.88 | 0.95 |
| Growth & Yield | |||||
| Revenue Growth | 46.6% | 46.6% | 5.9% | 2.3% | — |
| EPS Growth | 5.2% | 5.2% | -14.3% | — | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.1%
EPS terminal req.
$160.16
Spread vs growth
0.1%
5Y implied EPS CAGR
7.0%
EPS terminal req.
$193.80
Spread vs growth
-1.8%
10Y implied EPS CAGR
8.5%
EPS terminal req.
$312.11
Spread vs growth
-3.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.1%
Start / end P/E
14.2x → 13.1x
EPS bridge
131.11 → 137.97
Residual
-0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.